Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas

NCT02636725 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Alveolar Soft Part Sarcoma
Soft Tissue Sarcomas

Interventions

DRUG: Axitinib
DRUG: Pembrolizumab

Sponsor

Jonathan Trent, MD, PhD

Collaborators

[object Object]
[object Object]